$15.810
+0.213 (+1.35%)Zum Schluss
BLSM-News
BLSM-Events
BlossomHill Collaborates with Foundation Medicine to Develop CDx for EGFR C797S
BlossomHill Therapeutics announced a collaboration with Foundation Medicine to develop a companion diagnostic assay, or CDx, for the EGFR C797S resistance mutation. The collaboration will leverage the ongoing Phase 1/2 SOLARA clinical trial evaluating BH-30643 in the targeted treatment of epidermal growth factor receptor-mutant non-small cell lung cancer patients to validate the assay.
BlossomHill Presents Preclinical Data on BH-501284 at AACR Conference
BlossomHill Therapeutics announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research, AACR, Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, 2026, in San Diego, CA. Presentation highlights: BH-501284 exhibited potent and prolonged activity across a broad range of KRAS mutations; BH-501284 showed deep and durable antitumor activity across multiple preclinical KRAS-mutant tumor models; BH-501284 demonstrated deeper and more durable tumor regression than tricomplex RAS inhibitors; BH-501284 also demonstrated the potential to combine with an anti-PD-1 treatment.
Middle East War Influences Energy Prices and Markets
In the week ahead, the war in the Middle East will continue to dictate energy prices and financial markets as major central banks have hiked rates to combat inflation. Meanwhile, calls to slow AI advancement could impact the sector that has supported global stocks, credit issuance, and commodities. These matters, in addition to trade, are expected to be leading focal points in the highly anticipated meeting between U.S. and Chinese Presidents Trump and Xi.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Berkshire Hathawaynamed Warren Buffett as Chairman Emeritus and elected Howard Buffett as Chairman of the BoardApple'siPhone 18 Pro and Pro Max began hitting stores, though its foldable iPhone Duo will not be available for sale until October 23On Holdingannounced its entrance into the soccer market with "a major talent investment" into star Kylian Mbappe, a former brand ambassador for NikeSteelmakers Nucorand Steel Dynamicsboth guided Q3 earnings below consensusShares of U.S. and European carmakers were under pressure after Volkswagencut its operating-margin forecast2. WALL STREET CALLS:Wells Fargo downgraded Netflixto a sell-equivalent Underweight, calling the company's engagement trends "worrying"BTIG upgraded Etsyafter pullback, sees 24% upsideAccenturedowngraded to Neutral at Guggenheim after 52% reboundCiti upgraded StubHubto Buy on "robust" Q3 trendsYetiupgraded to Buy at Stifel after analyst day meeting3. AROUND THE WEB:Allspring Global Investments, acquired from Wells Fargoby GTCR and Reverence Capital in 2021 for $2.1B, is exploring a sale at a potential valuation of $4B, FT reportsMedia reports indicate the CEOs of OpenAI, Nvidiaand JPMorganare among executives slated to attend the Trump-Xi state dinnerNestlesaid it is assessing options for its Russian unit after Russian President Vladimir Putin ordered the company's Russian assets to be placed under temporary administration, WSJ reportsMetaCEO Mark Zuckerberg, NvidiaCEO Jensen Huang, and Teslaand SpaceX'sElon Musk recently spoke with President Trump and successfully stalled an AI regulatory plan proposed by Demis Hassabis, WSJ saysHondaintends to accelerate mass production of its next-generation hybrid vehicles by multiple months, Nikkei says4. MOVERS:Mistrasadvanced after announcing it will be acquired by H.I.G. Capital for $20.35 per share in cashCooper Companiesrose after Jana Partners urged the company to initiate an external search for its CEOXenonfell after pausing enrollment for its MDD and BPD studiesArray Technologiesdeclined after UBS downgraded the stock to NeutralFluenceclosed lower after Jefferies downgraded the stock to Hold5. EARNINGS/GUIDANCE:BlossomHill Therapeuticsreported Q2 results, with EPS lower year-over-yearSolowinreported results for FY26Rexford Industrialreaffirmed its outlook for FY26Progressivereported August EPSAutoZoneto report Q4 results on September 22INDEXES:The Dow fell 95.40, or 0.18%, to 51,682.64, the Nasdaq gained 104.25, or 0.39%, to 26,522.55, and the S&P 500 advanced 12.74, or 0.17%, to 7,650.50.
Stocks Drop as Treasury Yields Rebound
Stocks swung lower on Friday as Treasury yields rebounded and rekindled concerns of a deteriorating macroeconomic backdrop. The yield on the 10-year Treasury note rebounded above the 5% threshold as persistent uncertainty over Middle Eastern oil supply drove fuel and natural gas prices to rise. The prolonged threat of energy inflation has already impacted underlying consumer prices, driving the Fed to hike rates this week, while most FOMC members see the need for another hike.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Berkshire Hathawaynamed Warrenand elected Howard Buffett as Chairman of the BoardApple'siPhone 18 Pro and Pro Max, though its foldable iPhone Duo will not be available for sale until October 23On Holdingannounced its entrance into the soccer market withinto star Kylian Mbappe, a former brand ambassador for NikeSteelmakers Nucorand Steel Dynamicsbelow consensusThe FCCrequest to allow foreign investors to back its acquisition of Warner Bros Discovery, but said they could not hold voting stock2. WALL STREET CALLS:Wells FargoNetflixto a sell-equivalent Underweight, calling the company's engagement trends "worrying"BTIGEtsyafter pullback, sees 24% upsideAccentureto Neutral at Guggenheim after 52% reboundCitiStubHubto Buy on "robust" Q3 trendsYetito Buy at Stifel after analyst day meeting3. AROUND THE WEB:Allspring Global Investments, acquired from Wells Fargo (WFC) by GTCR and Reverence Capital in 2021 for $2.1B, is exploring a sale at a potential valuation of $4B, FT reportsSoftBankhas increased its loan backed by Armshares by $5B to $25B, Bloomberg saysNestlesaid it is assessing options for its Russian unit after Russian President Vladimir Putin ordered the company's Russian assets to be placed under temporary administration, WSJ reportsMetaCEO Mark Zuckerberg, NvidiaCEO Jensen Huang, and Teslaand SpaceX'sElon Musk recently spoke with President Trump and successfully stalled an AI regulatory plan proposed by Demis Hassabis, WSJ saysHondaintends to accelerate mass production of its next-generation hybrid vehicles by multiple months, Nikkei says4. MOVERS:Mistrasgains after announcing it will be acquired by H.I.G. Capital forin cashCooper Companiesincreases after Jana Partners urged the company tofor its CEOXenondeclines in New York afterfor its MDD and BPD studiesArray Technologiesfalls after UBSthe stock to NeutralFluencelower after Jefferiesthe stock to Hold5. EARNINGS/GUIDANCE:BlossomHill Therapeutics, with EPS lower year-over-yearSolowinRexford Industrialfor FY26ProgressiveAutoZoneon September 22INDEXES:Near midday, the Dow was down 223.14, or 0.43%, to 51,554.90, the Nasdaq was down 37.31, or 0.14%, to 26,380.99, and the S&P 500 was down 16.67, or 0.22%, to 7,621.09.
BlossomHill Therapeutics Achieves Significant Progress
"We've achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter," said Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill Therapeutics. "In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels. At ASCO in early June we presented the preliminary safety, PK and antitumor activities of BH-30643 in Phase 1 dose escalation of the SOLARA trial, along with the initial efficacy data in C797S-positive NSCLC. More recently we announced that BH-30643 received Fast Track designation, an important regulatory milestone that reflects the FDA's recognition of the potential for this molecule. We also presented encouraging safety data and early signs of anti-leukemic activity observed with BH-30236, our novel macrocyclic CLK inhibitor, both as a monotherapy and in combination with venetoclax, at EHA in the middle of June. We are now looking forward to our end-of-phase 1 meeting with the FDA later this year."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.